C

파마리서치

214450KOSDAQ의료용품 및 기타 의약 관련제품 제조업

52.1 / 100

Reference Date: 2026-07-24

Financial Score15.0 / 40
News Sentiment19.1 / 25
Momentum8.0 / 20
Disclosure10.0 / 15
AI Analysis: ROE is above the industry average but the high debt ratio poses financial risk. Surged 18.2% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Parmaresearch is a biopharmaceutical company specializing in regenerative medicine, leveraging PDRN/PN technology to develop and sell pharmaceuticals, medical devices, and cosmetics. Established in 2013 with a GMP-certified factory in Gangneung and expanded with a second plant in 2019, the company's key products include Regenix, Rejuran, and Conjuuran. It plans to expand into Asian, European, and North American markets, while its subsidiary also operates a botulinum toxin business.

Number of Employees

526people

Average Salary

68.5M KRW

Score Calculation Basis

Detailed Financial Score

PER
24.11Industry Average 15.181.5Point

1.6x industry avg (risky)

PBR
5.17Industry Average 1.090.0Point

4.7x industry avg (risky)

ROE
26.02Industry Average -4.893.5Point

Well below industry avg

Debt Ratio
28.95Industry Average 6.860.0Point

4.2x industry avg (risky)

Trend 2023~202510.0 / 10 points
Revenue Growth Rate
3.0 / 3

Avg ▲43.7% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲53.4% (2-year basis)

ROE Trend
4.0 / 4

Avg ROE 20.6% (improving, 3yr)

Detailed News Sentiment

30 totalPositive 21Neutral 5Negative 4Average Sentiment Score 76.5

Detailed Momentum

52-week position1.0Point

Near 52w low (19%, downtrend)

Current 360,000Won52-week high 711,00052-week low 276,000
1-month return6.0Point

1m +18.23% (strong rise)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0
  • Neutral결산실적공시예고2026-07-14
  • Neutral기업설명회(IR)개최2026-06-26